研究单位:[1]Beijing TongRen Hospital,Beijing,China[2]Anhui Palo Alto Pharmaceuticals, Inc.[3]The First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui,China[4]The Second Hospital of Anhui Medical University,Hefei,Anhui,China[5]Beijing Shijitan Hospital,Beijing,China[6]Dongfang Hospital Beijing University of Chinese Medicine,Beijing,China[7]Renmin Hospital of Wuhan University,Wuhan,Hubei,China[8]Northern Jiangsu People's Hospital,Yangzhou,Jiangsu,China[9]The Affiliated Hospital of Changchun University of Chinese Medicine,Changchun,Jilin,China[10]Tonghua Central Hospital,Tonghua,Jilin,China[11]Yanbian University Hospital(Yanbian Hospital),Yanji,Jilin,China[12]The Affiliated Hospital of Qingdao University,Qingdao,Shandong,China[13]Yantai Yuhuangding Hospital,Yantai,Shandong,China[14]Zibo Central Hospital,Zibo,Shandong,China[15]First Hospital of Shanxi Medical University,Taiyuan,Shanxi,China[16]Second Hospital of Shanxi Medical University,Taiyuan,Shanxi,China[17]Tianjin People's Hospital,Tianjin,China[18]Zhejiang Provincial People's Hospital,Hangzhou,Zhejiang,China
PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Nasal Spray in patients with seasonal allergic rhinitis.